Wedbush maintains Beam Therapeutics at Outperform, raises price target to $30 from $28

What happened

Wedbush kept its Outperform rating on Beam Therapeutics and raised its price target to $30 from $28, a 7.1% increase. The target represents 13.9% upside from the November 3 closing price of $26.33. Recent analyst targets listed in the article ranged from $28 to $80.

Confirmed

Global impact / market context

A higher target signals Wedbush sees more potential share-price gain, which may support investor interest in Beam. However, a target is an analyst estimate, not a forecast or guarantee; the wide range of recent targets shows analysts disagree substantially about the company’s value.

Analyst inference

Wedbush’s $30 target sits near the low end of the $28–$80 range across three recent analyst notes, while the shares closed at $26.33 on November 3. This gap may shape investor positioning, but the article gives no company operating or financial developments to explain the ratings.

Analyst inference

What to watch

1. Watch for later analyst rating or target changes: another revision could shift investor expectations, especially given the large difference between the recent targets cited. Analyst inference
2. Compare future company updates with the assumptions behind analyst targets; changes to research progress, spending, or funding needs could alter how investors value Beam. Analyst inference
3. Track whether the share price moves toward or away from Wedbush’s $30 target; the article reports a November 3 close of $26.33, not subsequent trading. Analyst inference

Evidence

• Original source link unavailable